1996
Elevated cerebrospinal fluid corticotropin-releasing ractor in Tourette's syndrome: Comparison to obsessive compulsive disorder and normal controls
Chappell P, Leckman J, Goodman W, Bissette G, Pauls D, Anderson G, Riddle M, Scahill L, McDougle C, Cohen D. Elevated cerebrospinal fluid corticotropin-releasing ractor in Tourette's syndrome: Comparison to obsessive compulsive disorder and normal controls. Biological Psychiatry 1996, 39: 776-783. PMID: 8731518, DOI: 10.1016/0006-3223(95)00221-9.Peer-Reviewed Original ResearchConceptsCorticotropin-releasing factorCSF corticotropin-releasing factorTourette syndromeObsessive-compulsive disorderNormal controlsCerebrospinal fluidPathobiology of TSOCD patientsMedication-free outpatientsCompulsive disorderLumbar cerebrospinal fluidNoradrenergic mechanismsHealthy controlsTS patientsObsessive-compulsive behaviorTic severityCardinal featuresClinical ratingsPatientsSyndromeRelated conditionsStandardized fashionNeurobiological mechanismsGroup differencesDisorders
1995
Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, tourette's syndrome, and healthy controls
Leckman J, Goodman W, Anderson G, Riddle M, Chappell P, McSwiggan-Hardin M, McDougle C, Scahill L, Ort S, Pauls D, Cohen D, Price L. Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, tourette's syndrome, and healthy controls. Neuropsychopharmacology 1995, 12: 73-86. DOI: 10.1016/0893-133x(94)00070-g.Peer-Reviewed Original ResearchObsessive-compulsive disorderTourette syndromeHealthy controlsOCD patientsTS patientsHomovanillic acidCerebrospinal fluidCerebrospinal fluid biogenic aminesMedication-free OCD patientsPathobiology of TSCSF HVA levelsCompulsive disorderLumbar cerebrospinal fluidConcentrations of tyrosineHVA levelsCSF norepinephrineNoradrenergic mechanismsSerotonergic mechanismsCSF MHPGSerotonergic systemHealthy subjectsHealthy volunteersNormal volunteersPatientsSyndromeCerebrospinal Fluid Biogenic Amines in Obsessive Compulsive Disorder, Tourette's Syndrome, and Healthy Controls
Leckman J, Goodman W, Anderson G, Riddle M, Chappell P, McSwiggan-Hardin M, McDougle C, Scahill L, Ort S, Pauls D, Cohen D, Price L. Cerebrospinal Fluid Biogenic Amines in Obsessive Compulsive Disorder, Tourette's Syndrome, and Healthy Controls. Neuropsychopharmacology 1995, 12: 73-86. PMID: 7766289, DOI: 10.1038/sj.npp.1380241.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderTourette syndromeHealthy controlsOCD patientsTS patientsHomovanillic acidCerebrospinal fluidCerebrospinal fluid biogenic aminesMedication-free OCD patientsPathobiology of TSCSF HVA levelsCompulsive disorderLumbar cerebrospinal fluidConcentrations of tyrosineHVA levelsCSF norepinephrineNoradrenergic mechanismsSerotonergic mechanismsCSF MHPGSerotonergic systemHealthy subjectsHealthy volunteersNormal volunteersPatientsSyndrome
1994
Enhanced stress responsivity of tourette syndrome patients undergoing lumbar puncture
Chappell P, Riddle M, Anderson G, Scahill L, Hardin M, Walker D, Cohen D, Leckman J. Enhanced stress responsivity of tourette syndrome patients undergoing lumbar puncture. Biological Psychiatry 1994, 36: 35-43. PMID: 8080901, DOI: 10.1016/0006-3223(94)90060-4.Peer-Reviewed Original ResearchConceptsTS patientsLumbar punctureNormal controlsTourette syndromeClinician ratingsEnhanced stress responsivityLumbar puncture stressUrinary norepinephrine excretionTourette syndrome patientsPeak ACTH levelsNorepinephrine excretionACTH levelsSympathetic systemAdrenal axisMedication responsivenessMore norepinephrinePhonic ticsSyndrome patientsUrinary catecholaminesMore ACTHPatientsTic severityNeuropsychiatric disordersSymptom severityStress responsivity
1993
Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: A pilot study
Chappell P, Leckman J, Scahill L, Hardin M, Anderson G, Cohen D. Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: A pilot study. Psychiatry Research 1993, 47: 267-280. PMID: 8396784, DOI: 10.1016/0165-1781(93)90084-t.Peer-Reviewed Original ResearchConceptsNormal control subjectsTourette syndromeTic frequencyControl subjectsTS patientsMicrograms/Clinician ratingsKappa agonist spiradolineInvolvement of opioidRole of opioidsGrowth hormone secretionDual modulatory effectsDose-response studyMotor tic frequencyMore growth hormoneTic symptomsHormone secretionNeuroendocrine effectsKappa receptorsPhonic ticsSpiradoline mesylateIntermediate doseLow doseModulatory effectsSpiradoline
1988
Tourette's Syndrome: Clinical and Neurochemical Correlates
RIDDLE M, LECKMAN J, ANDERSON G, ORT S, HARDIN M, STEVENSON J, COHEN D. Tourette's Syndrome: Clinical and Neurochemical Correlates. Journal Of The American Academy Of Child & Adolescent Psychiatry 1988, 27: 409-412. PMID: 3182595, DOI: 10.1097/00004583-198807000-00004.Peer-Reviewed Original ResearchConceptsTourette Syndrome Global ScalePHVA levelsTourette syndromeTS patientsLower CSF HVA levelsPlasma homovanillic acid levelsSimple motor ticsHomovanillic acid levelsCSF HVA levelsSignificant inverse correlationHVA levelsMotor restlessnessMotor ticsPretreatment levelsTotal symptomsNeurochemical correlatesTreatment responsePlasma 3Control groupPatientsSyndromeAcid levelsInverse correlationSignificant correlationIndividual items
1987
Parotid Gland Salivary Secretion in Tourette's Syndrome and Attention Deficit Disorder: A Model System for the Study of Neurochemical Regulation
COHEN D, ORT S, CARUSO K, ANDERSON G, HUNT R, SHAYWITZ B, KREMENITZER M, LECKMAN J. Parotid Gland Salivary Secretion in Tourette's Syndrome and Attention Deficit Disorder: A Model System for the Study of Neurochemical Regulation. Journal Of The American Academy Of Child & Adolescent Psychiatry 1987, 26: 65-68. PMID: 3034852, DOI: 10.1097/00004583-198701000-00013.Peer-Reviewed Original ResearchConceptsAttention deficit disorderTourette syndromeSalivary amylase concentrationTS patientsAmylase concentrationSalivary secretionNeurochemical regulationReceptor functioningTreatment of TSDeficit disorderSalivary amylase secretionParotid gland secretionSingle dosesSalivary volumeClonidinePatientsAmylase secretionSyndromeADD patientsSalivary measuresSecretionTotal amylaseSalivary amylaseDisordersChildren
1984
Parotid Salivary Response to Clonidine in Tourette's Syndrome: Indicator of Adrenergic Responsivity
SELINGER D, COHEN D, ORT S, ANDERSON G, CARUSO K, LECKMAN J. Parotid Salivary Response to Clonidine in Tourette's Syndrome: Indicator of Adrenergic Responsivity. Journal Of The American Academy Of Child & Adolescent Psychiatry 1984, 23: 392-398. PMID: 6205037, DOI: 10.1016/s0002-7138(09)60316-2.Peer-Reviewed Original ResearchConceptsDrug-free patientsSalivary volumeTS patientsTourette syndromeSingle doseAdrenergic receptorsLong-term clonidine treatmentAmylase secretionGood therapeutic responseYoung male patientParotid salivary responseAdrenergic responsivityClonidine treatmentSalivary amylase concentrationMale patientsTherapeutic responseNoradrenergic functioningAmylase concentrationPatientsClonidineParotid glandSyndromeSalivary responseT patientsTotal secretion
1983
Acute and Chronic CLonidine Treatment in Tourette's Syndrome A Preliminary Report on Clinical Response and Effect on Plasma and Urinary Catecholamine Metabolites, Growth Hormone, and Blood Pressure
LECKMAN J, DETLOR J, HARCHERIK D, YOUNG J, ANDERSON G, SHAYWITZ B, COHEN D. Acute and Chronic CLonidine Treatment in Tourette's Syndrome A Preliminary Report on Clinical Response and Effect on Plasma and Urinary Catecholamine Metabolites, Growth Hormone, and Blood Pressure. Journal Of The American Academy Of Child & Adolescent Psychiatry 1983, 22: 433-440. PMID: 6579101, DOI: 10.1016/s0002-7138(09)61504-1.Peer-Reviewed Original ResearchConceptsChronic clonidine treatmentClonidine treatmentTourette syndromeHomovanillic acidHuman growth hormoneClinical responseBlood pressureGrowth hormoneΑ2-adrenergic receptor agonistTreatment of TSUrinary catecholamine metabolitesClinical response dataChronic neuropsychiatric disorderPlacebo-controlled conditionsA Preliminary ReportClonidine therapyOral clonidineNoradrenergic receptorsSingle doseUnknown etiologyFunctional statusReceptor agonistClinical trialsDopaminergic systemTS patients
1981
Plasma free MHPG and neuroendocrine responses to challenge doses of clonidine in Tourette's Syndrome: Preliminary report
Young J, Cohen D, Hattox S, Kavanagh M, Anderson G, Shaywitz B, Maas J. Plasma free MHPG and neuroendocrine responses to challenge doses of clonidine in Tourette's Syndrome: Preliminary report. Life Sciences 1981, 29: 1467-1475. PMID: 6946271, DOI: 10.1016/0024-3205(81)90012-6.Peer-Reviewed Original ResearchConceptsFree MHPGPlasma free MHPGTourette syndromeChallenge doseNeuroendocrine responsesDoses of clonidineSingle oral dosesClonidine administrationResponsive patientsGH responseOral dosesMaintenance treatmentThyroxine indexClonidineTS patientsPatientsMHPGSyndromeT patientsNeuropsychiatric patientsPilot studyPreliminary reportMetabolic responseFurther investigationDose